These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23835249)

  • 1. Adverse effects of human immunoglobulin therapy.
    Stiehm ER
    Transfus Med Rev; 2013 Jul; 27(3):171-8. PubMed ID: 23835249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.
    Cherin P; Marie I; Michallet M; Pelus E; Dantal J; Crave JC; Delain JC; Viallard JF
    Autoimmun Rev; 2016 Jan; 15(1):71-81. PubMed ID: 26384525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events associated with intravenous immunoglobulin therapy.
    Hamrock DJ
    Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
    Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and use of therapeutic antibodies primarily of human origin.
    Stiehm ER; Keller MA; Vyas GN
    Biologicals; 2008 Nov; 36(6):363-74. PubMed ID: 18789721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
    Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
    Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.
    Schiavotto C; Ruggeri M; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):35-40. PubMed ID: 8039756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of human immunoglobulins--adverse reactions].
    Pituch-Noworolska A; Błaut-Szlósarczyk A; Zwonarz K
    Pol Merkur Lekarski; 2010 Sep; 29(171):202-5. PubMed ID: 20931833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and subcutaneous immunoglobulin G replacement therapy.
    Bonilla FA
    Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Effects of Immunoglobulin Therapy.
    Guo Y; Tian X; Wang X; Xiao Z
    Front Immunol; 2018; 9():1299. PubMed ID: 29951056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
    J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
    Shapiro RS; Borte M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):65-6. PubMed ID: 25546766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
    Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
    J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.